



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066516 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2420926, 2524003, Fax : 0731-2420926 • **CIN : L24233MP1985PLC002709**

To,
The Company Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001(M.H.)

Date: 14th February, 2015

To,
The Company Secretary
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Sub. : Un-Audited Financial results for the Quarter ended 31st December, 2014.

Dear Sirs,

In compliance with Clause 41 of the Listing Agreement, we are submitting herewith the Un-Audited Financial results for the quarter ended on 31st December, 2014 duly approved by the board of the Directors of the Company in their meeting held on 14/02/2015.

This is for your information and record.

Thanking you,
Yours Faithfully
For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
(DIN No: 00028819)





S.N. GADIYA
B.Com. F.C.A.

LIMITED REVIEW REPORT
FOR THE QUARTER ENDED ON 31st DECEMBER 2014

We have reviewed the accompanying statement of unaudited financial results of **M/S. BIOFIL CHEMICALS & PHARMACEUTICALS LTD** (CIN L24233MP1985PLC002709) for the quarter ended 31st December 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.N. Gadiya & Co.
Chartered Accountants
(Registration No: 002052C)

Place: Indore
Date : 14/02/2015




(S.N.Gadiya)
Proprietor
M. No: 071229


Un-Audited Financial Results of Quarter Ended Dec . 2014
31-12-2014 of M/s. Biofil Chemicals & Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN NO. L24233MP1985PLC002709

Un-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st December , 2014

Rs. In Lacs

PART I		(Rs. in Lakhs)					
	Particulars	Quarter Ended			Nine Month Period Ended		Year Ended
		Dec-14	Sep-14	Dec-13	Dec-14	Dec-13	Mar-14
	(Refer Notes Below)	Reviwed	Reviwed	Reviwed	Reviwed	Reviwed	(Audited)
1	Income from operations						
	(a) Net sales/ income from operations (Net of Excise duty)	71.26	71.71	196.76	193.02	250.59	488.88
	(b) Other operating income	15.62		115.56	15.62	0.00	228.28
	Total income from operations (net)	86.88	71.71	312.32	208.64	250.59	717.17
2	Expenses						
	(a) Cost of materials consumed	22.93	20.87	26.64	57.08	134.13	153.78
	(b) Purchases of stock-in-trade	35.42	15.83	157.31	72.15	60.41	308.10
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(8.15)	(3.25)	(2.22)	(9.26)	(28.75)	18.17
	(d) Employee benefits expense	8.62	7.06	4.36	22.00	19.38	41.30
	(e) Depreciation and amortisation expense	8.90	5.57	5.27	20.03	16.07	22.23
	(f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	8.25	6.90	77.36	22.83	17.83	99.14
	Total expenses	75.96	52.97	268.72	184.82	219.05	642.73
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	10.92	18.75	43.59	23.82	31.55	74.44
4	Other income	6.52		1.05	21.15	2.10	5.98
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	17.43	18.75	44.64	44.97	33.65	80.42
6	Finance costs	9.32	3.75	3.75	16.82	11.25	15.36
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	8.11	15.00	40.89	28.15	22.40	65.06
8	Exceptional items						1.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	8.11	15.00	40.89	28.15	22.40	64.06
10	Tax expense						12.40
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	8.11	15.00	40.89	28.15	22.40	51.66
12	Minority interest *						
13	Net profit/(loss) after taxes minority interest and share of profit/ (loss) of associates (13+14+ 15)	8.11	15.00	40.89	28.15	22.40	51.66
14	Paid-up equity share capital	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
	(Face Value of the Share shall be indicated)	10	10	10	10	10	10
15	Reserve excluding Revaluation Reserves						-1220.02
16.i	Earnings per share (before extraordinary items)						
	(of Rs. 10/- each) (not annualised):						
	(a) Basic	0.0050	0.0092	0.0251	0.0173	0.0138	0.0317
	(b) Diluted						



See accompanying note to the financial results

PART II

	Particulars	Dec-14	Sep-14	Dec-13	Dec-14	Dec-13	Mar-14
		Reviwed	Reviwed	Reviwed	Reviwed	Reviwed	(Audited)
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of shares	8655100	8655100	8655100	8655100	8655100	8655100
	- Percentage of shareholding	53.18	53.18	53.18	53.18	53.18	53.18
2	Promoters and Promoter Group Shareholding **						
	a) Pledged / Encumbered	Nil	Nil	Nil	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non - encumbered						
	- Number of shares	7618700	7618700	7618700	7618700	7618700	7618700
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	46.82	46.82	46.82	46.82	46.82	46.82

	Particulars	3 months ended
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	1
	Disposed of during the quarter	1
	Remaining unresolved at the end of the quarter	Nil


Notes

- Above Unaudited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their meeting held on 14th February 2015
- Figures have been regrouped wherever necessary.
- The Statuary auditors have carried out a limited review of the result for quarter ended 31st Dec- 2014
- Effective from April 1 2014, the company has provided depreciation with reference to the usefull lives of Tangible assets as specified in Schedule II of the Companices Act 2013. Accordingly, the carrying amount, net of residual value, as on that date have been depreciated over the revised remaining useful lives of the assets. As a result, the charge for depreciation is higher by Rs. 3.34 Lakhs for the quarter ended December 31, 2014.

Date : 14.02.2015

Place : indore

RAMESH SHAH
MANAGING DIRECTOR
(DIN : 00028819)



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709

Segmentwise Revenue, Results an Capital Employed for Quarter ended 31st Dec 2014
(Under Clause 41 Listing Agreement)

Quarter Ended

Rs. In lacs

S.No.	Segment Revenue	Quarter Ended			Nine Month Ended		31 March
		Dec 31 , 2014	Sep 30 , 2014	Dec 31 , 2013	Dec 31 , 2014	Dec 31 , 2013	
		Reviewed	Reviewed	Reviewed	Reviewed	Reviewed	Audited
		31-12-2014	30-09-2014	31-12-2013	31-12-2014	31-12-2013	31.03.2014
1	Segment Revenue						
	Pharma Unit	32.84	20.13	298.78	80.20	335.28	545.97
	Chemicals Division	27.79	48.71	26.75	91.10	129.92	144.65
	Plastic Division	10.63	2.87	(12.74)	21.72	26.00	26.54
	Other	15.62	0.00	1.05	30.25	3.15	6.49
	Gross Turnover	86.88	71.71	313.84	223.27	494.35	723.66
2	Segment Results						
	Pharma Unit	6.77	(2.51)	77.02	19.52	74.54	158.29
	Chemicals Division	6.25	22.80	(14.73)	25.98	6.36	(72.58)
	Plastic Division	(2.11)	(1.53)	(18.71)	(7.04)	(22.42)	(7.52)
	Other	6.52	0.00	1.05	6.52	1.05	1.12
	Total Segment Profit Before Tax	17.43	18.75	44.64	44.98	59.54	79.31
	Interest Income	0.00	0.00	-	-	-	0.43
	Interest Expenses	9.32	3.75	3.75	16.82	11.25	15.07
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	8.11	15.00	40.89	28.15	48.29	64.67
	Provision for current tax	0.00	0.00	-	-	-	12.32
	Profit After Tax	8.11	15.00	40.89	28.15	48.29	51.35
3	Capital Employed						
	(Segment Assets- Segment Liabilities)						
	Pharma Unit	177.46	220.71	163.62	177.46	163.62	137.25
	Chemicals Division	672.80	440.74	582.15	672.80	582.15	689.52
	Plastic Division	(32.99)	(25.06)	(23.18)	(32.99)	(23.18)	(52.88)
	Other	(1.90)	(2.21)	0.00	(1.90)	0.00	-
	Total Capital Employed	815.36	634.18	722.60	815.36	722.60	773.90

DATE : 14-02-2015
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Ramesh Shah

RAMESH SHAH
MANAGING DIRECTOR
(DIN : 00028819)

